Moclobemide-d4 is intended for use as an internal standard for the quantification of moclobemide by GC- or LC-MS. Moclobemide is a reversible inhibitor of monoamine oxidase A (MAO-A; Ki = 0.005 µM).1 It is selective for MAO-A over MAO-B (Ki = 1.08 µM). Chronic administration of moclobemide (15 mg/kg) decreases immobility in the forced swim test in rats.2 It increases time spent in the open arms of the elevated plus maze in rats, indicating anxiolytic-like activity, when administered chronically at a dose of 20 mg/kg.3 Formulations containing moclobemide have been used in the treatment of major depressive disorder, bipolar disorder, and social anxiety.
1.Jagrat, M., Behera, J., Yabanoglu, S., et al.Pyrazoline based MAO inhibitors: Synthesis, biological evaluation and SAR studiesBioorg. Med. Chem. Lett.21(14)4296-4300(2011) 2.Cryan, J.F., Page, M.E., and Lucki, I.Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatmentPsychopharmacol. (Berl).182(3)335-344(2005) 3.Frank, M., and Braszko, J.J.Moclobemide enhances aversively motivated learning and memory in ratsPol. J. Pharmacol.51(6)497-503(1999)